Zura(US:ZURA)2025-11-13 11:30Financial Position - Zura Bio reported cash and cash equivalents of $139.0 million as of September 30, 2025, expected to fund operations through 2027[4]. - The Company’s accumulated deficit increased to $207.4 million as of September 30, 2025, compared to $155.9 million at the end of 2024[16]. - Zura Bio's total assets decreased to $143.9 million as of September 30, 2025, from $179.5 million at the end of 2024[16]. Research and Development - Research and Development (R&D) expenses for Q3 2025 were $11.9 million, up from $6.0 million in Q3 2024, reflecting ongoing Phase 2 clinical trials for tibulizumab[7]. - The Company is advancing two Phase 2 clinical trials for tibulizumab, with topline data expected in the second half of 2026 for both trials[4]. - Zura Bio's lead product candidate, tibulizumab, is being evaluated in two Phase 2 studies targeting systemic sclerosis and hidradenitis suppurativa[11]. - The Company continues to monitor timelines and evaluate strategies for its clinical studies in light of competitive patient enrollment and regulatory factors[3]. Operating Expenses - General and Administrative (G&A) expenses decreased to $7.6 million in Q3 2025 from $13.3 million in Q3 2024, primarily due to a one-time non-cash expense in share-based compensation in the previous year[8]. - Total operating expenses for Q3 2025 were $19.5 million, slightly higher than $19.3 million in Q3 2024[18]. Net Loss - Net loss for Q3 2025 was $20.0 million, or $0.21 per share, compared to a net loss of $22.9 million, or $0.26 per share, in Q3 2024[9].